Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 29 Mar 2016

Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

Bone Therapeutics (Belgium) has released its financial results for 2015, which show a solid cash position and promising results in treating Bone conditions in ongoing clinical trials. This Belgian Biotech is developing cell therapies to treat a bone diseases like osteoporosis with considerable success so far – and 2015 was a year with plenty of important milestones. These […]

March 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 29 Mar 2016

Interviewing the Managing Director of the $750M Venture Fund of Novartis

This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of the Novartis Venture Fund. He almost played at home as he is living few dozen of kilometres outside the city in the lovely Swiss countryside. Novartis Venture Fund originates, as its name can tell, from […]

March 29, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 28 Mar 2016

Infographic: A Handy Guide to the European Synthetic Biology Startup Scene

The rise of Synthetic biology has radicalised how the biotech industry innovates, develops and invests. Here is an infographic put together by SynBioBeta (the ‘Activity hub for the SynBio industry’). Synbio is now an essential source of research, particularly in the Greentech field. For example, Deinove (France) has signed major partnerships with the US on Synbio […]

March 28, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Mar 2016

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma. Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics […]

March 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 25 Mar 2016

Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle and, of course the Eiffel Tower, the Louvre and le baguette, Paris is also the home of OSE Pharma, our Biotech of the Week. City: Paris (France) Founded: 2012 Employees: N/A Financial Data: €24.3M total raised (as of […]

March 25, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 24 Mar 2016

Endeavouring to Establish Europe’s Largest MedTech Fund

The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide! Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure […]

March 24, 2016 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT

News and Trends 24 Mar 2016

Leading German Biotech recruits New talent for Fight against Alzheimer’s

Probiodrug (Germany) has hired Mark Booth as Chief Business Officer to propel this Pharma’s global strategy. Among other important roles, Booth was president of Takeda North America. Probiodrug is a Biopharma focused on developing treatments for Alzheimer’s disease. Its strategy is based on the elimination of pyroglutamated Abeta (pGlu), which is one of the way Alzheimer’s […]

March 24, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 23 Mar 2016

French Microbiome Startup Gets €10M to Start Clinical Trials

MaaT Pharma (France) has raised €10M in a series A round, which will allow it to start clinical development of its autologous therapy for imbalance of the Gut Microbiome. MaaT Pharma is developing microbiome-based therapies with an autologous (self-sourced) approach. This means that the patient suffering from dysbiosis is treated with their own microbiome, samples of which were […]

March 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 23 Mar 2016

Leading German Biotech Spins Off a New Startup in Autoimmune Diseases

Evotec (Germany) has launched a spin-off, Topas Therapeutics, to create nanoparticle-based therapeutics to treat immunological disorders. After starting a collaboration for microbiome-related diseases and entering the immuno-oncology field, Evotec is creating a spin-off dedicated to autoimmune diseases. This new biotech, Topas Therapeutics, is based on a technology that induces liver tolerance to specific antigens. This platform could be used to create breakthrough therapies for […]

March 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 23 Mar 2016

No, this French Startup didn’t Discover the Cure for HIV…

This is the story of a French doctor and his start-ups which have been trying to develop a cure for HIV for the last 10 years. The problem resides in exaggerating, not publishing data…and then repeating this process again and again. Last week, the professor Erwann Loret and his start-up Biosantech did a press conference to announce new “breakthrough” […]

March 23, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 22 Mar 2016

Eurostars grants Metrion €2.2M for Novel Drug Discovery Tests

Metrion Biosciences (UK) is receiving €2.2M in funding for its project to develop phenotypic cardiac safety assays, that could make drug discovery cheaper and faster. Metrion is a Contract Research Organization out of the Babraham Institute in Cambridge (one of the 10 hottest bioincubators in Europe). It provides screening services for drugs still in the discovery […]

March 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT